Adaptive Trial Market Dynamics

Report Overview

Pharmaceutical companies are under tremendous pressure to lower costs and improve the ROI on their R&D spending. How bad is it? In a relatively unprecedented move, large pharmaceutical companies have actually come together to work together for the sole purpose of reducing clinical trial costs.

Pharmaceutical companies have collaborated before on areas considered not directly competitive, like finding variants in the human genome and biomarkers to predict disease and the effectiveness of drugs. But the people behind the new effort said it would be the largest of its kind.

What you will learn:

• Compare your own organizations activities against the industries level of adoption
• The types of studies conducted most frequently, those that are given the most attention, and whether adaptive trials are gaining/losing momentum
• Sponsors’ drivers for conducting adaptive trials and the common barriers standing in the way of adoption
• Which service providers are perceived as leaders in adaptive clinical trials, which are used most often, and who has the most proposal activity
• The therapeutic areas that are most attractive and best fit for adaptive designs

How you can use this report:

• Identify trends in adaptive trial conduct and outsourcing (i.e. drivers and barriers, outsourcing trial design vs. clinical operations, levels of adoption, etc.)
• Set realistic goals by understanding sponsors’ expectations for adaptive trial timing and cost
• Make more informed decisions regarding marketing messages and customer targeting

Report Contents:

1. Adaptive Trial Market Dynamics (i.e. growth and adoption; perceptions of how risky adaptive trials are)
2. Outsourcing Environment (including service provider analyses)
3. Study-specific Usage and Trends
4. Departmental/ Organizational Impacts